Format

Send to:

Choose Destination
See comment in PubMed Commons below
Q J Nucl Med. 1995 Dec;39(4 Suppl 1):3-8.

The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.

Author information

  • 1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0028, USA.

Abstract

Metaiodobenzylguanidine (MIBG) has been in clinical use for 15 years and has been shown to have high sensitivity (about 85%) and specificity (> 95%) for the location of all types of pheochromocytomas. Similar results have been achieved with neuroblastomas. A wide range of other neuroendocrine lesions including carcinoids, medullary thyroid cancer and nonsecretory paragangliomas may also be imaged, but the lower sensitivity. The newly developed radiolabeled somatostatin analogs may have greater utility for these lesions. MIBG scintigraphy may also provide a unique in vivo probe for study of the sympathetic autonomic nervous system, particularly in the heart. Various radiolabels for MIBG and its analogs permit planar scintigraphy, SPECT, PET, intraoperative probe localization and radiopharmaceutical therapy.

PMID:
9002740
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk